U.S. Veterans Affairs Secures Opioid-Free Pain Relief Technology Through 2031
Washington, Wednesday, 10 June 2026.
On June 10, 2026, the U.S. Veterans Affairs renewed its contract with ZetrOZ Systems through 2031, signaling a major institutional shift toward opioid-free, non-invasive pain management technology.
A Strategic Shift in Veteran Healthcare
On June 10, 2026, the U.S. Department of Veterans Affairs (VA) officially announced the renewal and expansion of its contract with Trumbull, Connecticut-based medical technology firm ZetrOZ Systems [1]. Originally approved in April 2026, this agreement extends the institutional partnership through the year 2031, representing a forward-looking commitment of 5 years [1]. The contract ensures that military veterans maintain and expand their access to the company’s sustained acoustic medicine technology, specifically the sam® wearable ultrasound units [1].
Economic Alignment and Domestic Production
Beyond clinical applications, the contract renewal highlights a strategic alignment with federal economic priorities. The sam® devices are designed and manufactured entirely within the United States, allowing the VA’s procurement to support the federal Made in America Manufacturing Initiative [1]. ZetrOZ Systems’ relationship with the federal government dates back to 2021, when the company was first awarded a Federal Supply Schedule Service contract [1].
Clinical Validation and Patient Outcomes
The institutional confidence in ZetrOZ Systems’ technology is underpinned by extensive clinical validation. The efficacy of the sustained acoustic medicine technology is documented in over 40 peer-reviewed studies [1]. Furthermore, the sam® 2.0 unit has been awarded the Ease-of-Use® Certification from the Arthritis Foundation, indicating that the device is accessible and manageable for patients suffering from joint pain and limited mobility [1].